Iberdomide for Neuroblastoma

This trial explores the effectiveness of iberdomide, combined with other treatments, for individuals with neuroblastoma—a cancer that recurs, resists treatment, or worsens after previous therapies. Iberdomide aids the immune system in targeting and destroying cancer cells, while chemoimmunotherapy combines chemotherapy and immunotherapy to halt cancer growth. The trial examines the optimal dose and side effects of iberdomide. It suits individuals with neuroblastoma that has returned or not improved after prior chemoimmunotherapy. Participants must have a confirmed neuroblastoma diagnosis and have tried certain prior treatments that ceased to work. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to be among the first to receive this potentially groundbreaking therapy.

The trial protocol does not specify whether you need to stop taking your current medications. However, you must not have received certain medications like enzyme-inducing anticonvulsants or drugs that strongly affect CYP3A4 within a specific period before joining the study. It's best to discuss your current medications with the trial team.

Research has shown that iberdomide is generally well-tolerated in other conditions. In studies involving patients with multiple myeloma, a type of blood cancer, iberdomide demonstrated a promising safety record. For instance, one study found that patients could take the treatment for up to 36 cycles, indicating it was manageable over a long period. However, some reports noted serious side effects, such as infections, in a small number of patients. This suggests that while the treatment has been safe for many, there is a chance of experiencing side effects.

When combined with chemoimmunotherapy, iberdomide might be safe and effective. Chemoimmunotherapy combines chemotherapy, which kills or stops the growth of cancer cells, with immunotherapy, which helps the immune system fight cancer. Researchers are currently studying iberdomide with these therapies to ensure its safety and effectiveness in treating relapsed or refractory neuroblastoma, a type of cancer that mostly affects children.

Researchers are excited about iberdomide for neuroblastoma because it introduces a novel mechanism of action, potentially offering a new way to tackle this cancer. Unlike standard treatments that often involve chemotherapy drugs like cyclophosphamide and topotecan, iberdomide acts as an immunomodulatory agent, which means it can enhance the body's immune response against cancer cells. This unique approach could lead to improved outcomes for patients who have limited options with existing therapies. By combining iberdomide with conventional treatments, there's hope for more effective and comprehensive cancer control.

This trial will evaluate the effectiveness of iberdomide combined with chemoimmunotherapy drugs for neuroblastoma. Research has shown that iberdomide may be promising in treating multiple myeloma, a type of blood cancer, with a high overall response rate. Some studies reported that up to 93% of patients responded well, with many experiencing long periods without disease progression. Although these results pertain to a different cancer, they suggest iberdomide might help the immune system effectively find and destroy cancer cells. In this trial, one arm will include iberdomide combined with cyclophosphamide, topotecan, dinutuximab, and sargramostim, aiming to boost the body's immune response alongside traditional cancer treatments. This approach could be effective in managing relapsed or difficult-to-treat neuroblastoma, but more specific data is needed for this condition.¹²³⁴⁵